CG
CRSP icon

Cutler Group’s CRISPR Therapeutics CRSP Stock Holding History

Cutler Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,200
Closed -$474K – 4513
2022
Q3 		$474K Sell
11,200
-8,400
-43% -$609K 0.03% 546
2022
Q2 		$639K Sell
19,600
-8,200
-29% -$482K 0.04% 461
2022
Q1 		$1.01M Sell
27,800
-10,700
-28% -$672K 0.05% 382
2021
Q4 		$1.19M Buy
38,500
+22,800
+145% +$1.99M 0.05% 400
2021
Q3 		$623K Sell
15,700
-200
-1% -$25.1K 0.03% 678
2021
Q2 		$476K Buy
15,900
+4,100
+35% +$499K 0.02% 782
2021
Q1 		$587K Buy
11,800
+1,200
+11% +$181K 0.03% 659
2020
Q4 		$352K Buy
10,600
+9,700
+1,078% +$1.15M 0.02% 796
2020
Q3 		$12K Buy
900
+400
+80% +$35.5K ﹤0.01% 2845
2020
Q2 		$1K Hold
500
– – ﹤0.01% 3985
2020
Q1 		$5K Hold
500
– – ﹤0.01% 3060
2019
Q4 		$3K Hold
500
– – ﹤0.01% 3252
2019
Q3 		$5K Hold
500
– – ﹤0.01% 2996
2019
Q2 		$5K Hold
500
– – ﹤0.01% 3066
2019
Q1 		$7K Hold
500
– – ﹤0.01% 2704
2018
Q4 		$9K Sell
500
-2,600
-84% -$90.4K ﹤0.01% 2579
2018
Q3 		$33K Buy
3,100
+900
+41% +$47.1K ﹤0.01% 1882
2018
Q2 		$2K Sell
2,200
-5,500
-71% -$313K ﹤0.01% 3534
2018
Q1 		$15K Buy
+7,700
New +$318K ﹤0.01% 2476
2017
Q4 		– Sell
-4,700
Closed -$4K – 5035
2017
Q3 		$4K Buy
4,700
+3,500
+292% +$63.5K ﹤0.01% 4531
2017
Q2 		$2K Buy
+1,200
New +$19.8K ﹤0.01% 5462

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's CRSP Position: Q1 2024 in Review

Cutler Group increased its CRISPR Therapeutics (CRSP) stake by 250% in Q1 2024, buying an estimated $35.8K and bringing the position to 700 shares worth $47K. The position accounts for 0.02% of the portfolio, ranked #699.

Cutler Group first reported a position in CRSP in Q2 2017 and has held it in 19 quarters since. The position peaked at $1.95M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Cutler Group held 700 shares of CRISPR Therapeutics worth $47K as of Q1 2024.
  • Cutler Group bought 500 CRISPR Therapeutics shares in Q1 2024, an estimated $35.8K.
  • CRISPR Therapeutics made up 0.02% of Cutler Group's portfolio in Q1 2024, its #699 holding.
  • Cutler Group first reported a position in CRISPR Therapeutics in Q2 2017 and has held it in 19 quarters since.
  • Cutler Group's CRISPR Therapeutics position peaked at $1.95M in Q4 2020.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.